ArticleHuman mutation2026
Integrative Multiomics Analysis Identifies DKK3 as a Germline Susceptibility-Related Regulator of Risperidone Response and Metabolic Risk in Schizophrenia.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Risperidone is a widely used second-generation antipsychotic for schizophrenia, known for its clinical efficacy but also for long-term metabolic side effects, including weight gain and glucose-lipid dysregulation. Although its therapeutic effects have been well characterized, the molecular basis linking its benefits and adverse metabolic outcomes remains poorly understood. Methods: To identify genes mediating both therapeutic and metabolic responses to risperidone, we conducted an integrative multiomics study combining large-scale genetic association data with transcriptomic and epigenetic profiling. Differentially expressed genes following risperidone exposure were intersected with schizophrenia- and metabolism-associated loci using summary data-based Mendelian randomization analysis based on GWAS summary statistics and eQTL data to uncover germline variants, germline susceptibility, and potential germline alteration. DNA methylation profiling from patient-derived peripheral blood mononuclear cells (PBMCs) was used for regulatory validation. Results: We identified 120 genes significantly modulated by risperidone, among which DKK3, EEF1A1, and PRKAA1 were causally associated with schizophrenia and metabolic traits through germline mutation-related regulatory evidence. Notably, DKK3 was downregulated after risperidone exposure and exhibited promoter hypermethylation, consistent with epigenetic regulation interacting with germline alteration and germline susceptibility. Functional correlation analysis revealed that lower DKK3 expression was associated with glycolipid dysregulation, supporting its role as a molecular bridge between antipsychotic action and metabolic liability. Conclusion: Our findings identify DKK3 as a germline mutation-related and epigenetically regulated candidate that bridges risperidone's neuropsychiatric benefits with its metabolic risks. This work offers novel insight into the shared molecular basis of antipsychotic response and side effects and suggests DKK3 as a promising biomarker for personalized treatment strategies in schizophrenia informed by germline regulatory variation and potential germline alteration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.